Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 61.33 CNY -5.5% Market Closed
Market Cap: 45.5B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hangzhou Tigermed Consulting Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Equity
ÂĄ20.8B
CAGR 3-Years
7%
CAGR 5-Years
40%
CAGR 10-Years
39%
WuXi AppTec Co Ltd
SSE:603259
Total Equity
ÂĄ54.7B
CAGR 3-Years
14%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Equity
ÂĄ13B
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Equity
ÂĄ40.7B
CAGR 3-Years
7%
CAGR 5-Years
37%
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Total Equity
ÂĄ8.6B
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Total Equity
ÂĄ5.5B
CAGR 3-Years
144%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
45.5B CNY
Industry
Life Sciences Tools & Services

Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.

Intrinsic Value
70.64 CNY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Total Equity?
Total Equity
20.8B CNY

Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Total Equity amounts to 20.8B CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
39%

Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for Hangzhou Tigermed Consulting Co Ltd have been 7% over the past three years , 40% over the past five years , and 39% over the past ten years .

Back to Top